by 
PCR Technologies Market Key Takeaways
- In terms of revenue, the global PCR technologies market was valued at USD 15.78 billion in 2024.
- It is projected to reach USD 31.39 billion by 2034.
- The market is expected to grow at a CAGR of 7.12% from 2025 to 2034
- North America led the PCR technologies market with a 44% market share in 2024.
- Asia Pacific is expected to expand at the fastest CAGR in the market between 2025 and 2034.
- By product type, the instruments segment dominated the market with a 43% share, under which the real-time PCR systems sub-segment held a maximum share in 2024.
- By product type, the digital PCR systems sub-segment is anticipated to grow at a remarkable CAGR between 2025 and 2034.
- By technology type, the real-time PCR segment held a 45% market share in 2024.
- By technology type, the digital PCR segment is expected to expand at a notable CAGR over the projected period.
- By application, the clinical diagnostics segment dominated the market with a 40% market share, under which the infectious disease testing sub-segment captured a maximum share in 2024.
- By application, the oncology & genetic disorder testing sub-segment is expected to expand at a significant CAGR over the projected period.
- By end user, the hospitals & diagnostic laboratories segment captured a 48% share of the market in 2024.
- By end user, the pharmaceutical & biotechnology companies segment is expected to expand at a notable CAGR over the projected period.
How AI Is Transforming PCR Technologies
Artificial intelligence (AI) is reshaping the landscape of Polymerase Chain Reaction (PCR) technologies by significantly improving diagnostic accuracy and reducing turnaround times. Advanced AI algorithms can now process large, complex datasets to detect gene expression patterns in real time, streamlining the detection of infectious diseases such as COVID-19 and antimicrobial resistance. These innovations not only enhance clinical laboratory workflows and reduce human error but also accelerate responses to critical public health challenges—including oncology, virology, and personalized medicine. By analyzing vast volumes of PCR data quickly and accurately, AI is making diagnostic procedures faster, smarter, and more reliable.
Market Overview
The PCR technologies market involves the development, manufacturing, and sales of instruments, reagents, consumables, and software used to amplify and analyze DNA/RNA sequences. PCR is a foundational molecular biology technique employed extensively in clinical diagnostics, research, forensics, agriculture, and environmental testing. The market is driven by the increasing demand for rapid and accurate diagnostics, particularly for infectious diseases (e.g., COVID-19) and genetic disorders, as well as advancements in real-time and digital PCR platforms. Innovations in multiplexing, automation, and miniaturization also propel market growth.
PCR Technologies Market Growth Factors
- Increasing Demand for Molecular Diagnostics:The increased prevalence of infectious and genetic disorders will drive the use of PCR in clinical diagnostics, particularly for rapid and accurate pathogen identification.
- Advancements in PCR Platforms: Innovations in real-time and digital PCR technology continue to drive growth through improvements in sensitivity, speed, and automation, thereby increasing the number of applicable settings.
- Additional Uses in Oncology and Genetic Testing: PCR is heavily utilized in cancer diagnostics, mutation testing, and personalized medicine, and its use is expected to increase in precision health due to its utility.
- Increase in Genomics and Life Science Research: With the increase in genome mapping, biomarker discovery, and continuity in academic research, the demand for superior, reliable PCR-based laboratory tools will only continue to rise.
Opportunity
Growing Demand for Point-of-Care Testing
The rising shift toward decentralized and point-of-care (POC) diagnostics is opening significant growth opportunities in the PCR technologies market. As the need for rapid, on-site detection of infectious diseases increases—especially in rural and resource-limited areas—there is a growing demand for portable PCR solutions that deliver accurate results quickly and efficiently.
- In July 2025, Bio-Rad Laboratories announced the development of four new Droplet Digital™ PCR (ddPCR™) platforms, emphasizing their potential use in mobile and point-of-care environments to support faster, more accessible diagnostics.
Recent Developments
- In May 2025, Diagnostics.ai launched the industry’s first fully transparent machine-learning platform for clinical real-time PCR diagnostics, compliant with CE-IVDR and MHRA. It clearly shows how each result was derived, offering ≥99.9% accuracy and real‑time auditability across Europe. ”
- In February 2025, Bio-Rad Laboratories, Inc. signed an agreement to acquire Stilla Technologies, a digital PCR specialist. The potential acquisition would enhance Bio Rad’s portfolio in high precision molecular diagnostics.
- In November 2024, Takara Bio USA, Inc. unveiled the SmartChip ND Real Time PCR System, a high throughput, research use only qPCR platform supporting up to 5,184 nanoliter reactions per chip, delivering fast, cost effective infectious disease testing.
- In September 2024, Qiagen introduced a digital PCR (dPCR) system tailored for oncology clinical testing, enabling more accurate and quantitative mutation analysis in cancer diagnostics.
Also Read: PCR Plastic Packaging Market
PCR Technologies Market Top Key Players
- Abbott Laboratories
- Agilent Technologies
- Bio-Rad Laboratories
- Danaher Corporation (includes Cepheid, Beckman Coulter)
- F. Hoffmann-La Roche AG
- GE Healthcare (now Cytiva)
- Hologic, Inc.
- Illumina, Inc.
- Merck KGaA (MilliporeSigma)
- Myriad Genetics
- PerkinElmer, Inc.
- QIAGEN N.V.
- Qiagen Digital Insights
- Siemens Healthineers
- Sysmex Corporation
- Thermo Fisher Scientific
- TIB Molbiol
- Takara Bio Inc.
- Bio-Techne Corporation
- LGC Limited
